UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1162-10
Program Prior Authorization/Notification
Medication Odomzo® (sonidegib)
P&T Approval Date 10/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 10/2021, 10/2022,
10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Odomzo® (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of adult
patients with locally advanced basal cell carcinoma (BCC), that has recurred following surgery or
radiation therapy, or who are not candidates for surgery or radiation therapy.1
The National Comprehensive Cancer Network (NCCN) also recommends Odomzo for the
recurrence of basal cell carcinoma with nodal disease and for treatment of diffuse basal cell
carcinoma (BCC) formation (e.g., Gorlin syndrome, other genetic forms of multiple BCC).
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Odomzo will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Basal Cell Carcinoma
1. Initial Authorization
a. Odomzo will be approved based on one of the following criteria:
(1) Diagnosis of nodal metastatic basal cell carcinoma
-OR-
(2) Diagnosis of diffuse basal cell carcinoma (BCC) formation (e.g., Gorlin
© 2024 UnitedHealthcare Services, Inc.
1
syndrome, other genetic forms of multiple BCC)
-OR-
(3) Both of the following:
(a) Diagnosis of locally advanced basal cell carcinoma
-AND-
(b) One of the following:
i. Cancer has recurred following surgery
ii. Cancer has recurred following radiation
iii. Patient is not a candidate for surgery
iv. Patient is not a candidate for radiation
Authorization will be issued for 12 months.
2. Reauthorization
a. Odomzo will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Odomzo
therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
2
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Odomzo [package insert]. Sun Pharmaceutical Industries, Inc.: Cranbury, NJ; August 2023.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
https://www.nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia.
Accessed September 6, 2024.
Program Prior Authorization/Notification - Odomzo (sonidegib)
Change Control
10/2015 New notification.
9/2016 Annual review. Minor formatting changes to background and updated
references.
9/2017 Annual Review. Updated references.
9/2018 Annual Review. Updated references.
9/2019 Annual review. Added metastatic basal cell carcinoma diagnosis.
Updated references. Added general NCCN recommended review
criteria.
9/2020 Annual review. No changes to coverage rationale.
10/2021 Annual review. Added diffuse basal cell carcinoma (BCC) formation
per NCCN recommendations. Updated references.
10/2022 Annual review. No changes to coverage rationale. Added state mandate.
Updated references.
10/2023 Annual review. No changes to coverage rationale. Updated references.
10/2024 Updated background and coverage criteria per NCCN recommendations
to reflect that Odomzo is recommended for basal cell carcinoma with
nodal metastases but not with distant metastases. Updated references.
© 2024 UnitedHealthcare Services, Inc.
3